These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. New developments in allergen immunotherapy. Vadlamudi A; Shaker M Curr Opin Pediatr; 2015 Oct; 27(5):649-55. PubMed ID: 26241500 [TBL] [Abstract][Full Text] [Related]
4. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. Nolte H; Maloney J Allergol Int; 2018 Jul; 67(3):301-308. PubMed ID: 29759659 [TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of non-grass pollens respiratory allergies in Italy and effects of specific sublingual immunotherapy: The Rainbow Trial, a multicentre 3-year prospective observational study. Milani M; Pecora S; Eur Ann Allergy Clin Immunol; 2011 Aug; 43(4):111-6. PubMed ID: 21980798 [TBL] [Abstract][Full Text] [Related]
6. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. Calderon MA; Casale TB; Nelson HS; Demoly P J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829 [TBL] [Abstract][Full Text] [Related]
7. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609 [TBL] [Abstract][Full Text] [Related]
8. Sublingual immunotherapy: the U.S. experience. Nelson HS Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):663-8. PubMed ID: 24169432 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials. Tao L; Shi B; Shi G; Wan H Clin Respir J; 2014 Apr; 8(2):192-205. PubMed ID: 24118881 [TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment. de Bot CM; Moed H; Berger MY; Röder E; de Groot H; de Jongste JC; van Wijk RG; van der Wouden JC BMC Fam Pract; 2008 Oct; 9():59. PubMed ID: 18937864 [TBL] [Abstract][Full Text] [Related]
11. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432 [TBL] [Abstract][Full Text] [Related]
12. Sublingual immunotherapy: what we can learn from the European experience. Linkov G; Toskala E Curr Opin Otolaryngol Head Neck Surg; 2014 Jun; 22(3):208-10. PubMed ID: 24801802 [TBL] [Abstract][Full Text] [Related]
13. Sublingual Immunotherapy Dosing Regimens: What Is Ideal? Jin JJ; Li JT; Klimek L; Pfaar O J Allergy Clin Immunol Pract; 2017; 5(1):1-10. PubMed ID: 28065336 [TBL] [Abstract][Full Text] [Related]
14. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Didier A; Wahn U; Horak F; Cox LS Expert Rev Clin Immunol; 2014 Oct; 10(10):1309-24. PubMed ID: 25205329 [TBL] [Abstract][Full Text] [Related]
15. Sublingual immunotherapy for allergic rhinitis: where are we now? Incorvaia C; Mauro M; Ridolo E Immunotherapy; 2015; 7(10):1105-10. PubMed ID: 26507464 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sublingual allergen immunotherapy. DuBuske L Allergy Asthma Proc; 2022 Jul; 43(4):272-280. PubMed ID: 35818141 [TBL] [Abstract][Full Text] [Related]